Victor Grifols Deu
Director/Board Member en GRIFOLS, S.A. .
Fortuna: 131 654 $ al 31/03/2024
Perfil
En la actualidad, Victor Grifols Deu ocupa el cargo de Consejero Delegado Conjunto y Director Ejecutivo de Grifols SA. El Sr. Deu también forma parte del consejo de administración de Araclon Biotech SL. Se licenció en el Institut Qumic De Sarri y obtuvo un MBA en la UCD Michael Smurfit Graduate School of Business.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
GRIFOLS, S.A. CLASS A
0.00% | 31/12/2022 | 14 620 ( 0.00% ) | 131 654 $ | 31/03/2024 |
Cargos activos de Victor Grifols Deu
| Empresas | Cargo | Inicio |
|---|---|---|
| GRIFOLS, S.A. | Director/Board Member | 30/05/2016 |
Araclon Biotech SL
 Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Director/Board Member | - |
Formación de Victor Grifols Deu.
| UCD Michael Smurfit Graduate School of Business | Graduate Degree |
| Institut Químic De Sarrià | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GRIFOLS, S.A. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Araclon Biotech SL
Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Commercial Services |
- Bolsa de valores
- Insiders
- Victor Grifols Deu
